Case W. McNamara

Case W. McNamara

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMalina Bakowski
Malina Bakowski
NBNathan Beutler
Nathan Beutler
KWKaren C. Wolff
Karen C. Wolff
MKMelanie G. Kirkpatrick
Melanie G. Kirkpatrick
ECEmily Chen
Emily Chen
TRThomas F. Rogers
Thomas F. Rogers
The ongoing pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), necessitates strategies to identify prophylactic and therapeutic drug candidates for rapid clinical deployment. Here, we describe a screening pipeline for the discovery of efficacious SARS-CoV-2 inhibitors. We screen a best-in-class drug repurposing library, ReFRAME, against two high-throughput, high-content imaging infection assays: one using HeLa cells expressing SARS-CoV-2 receptor ACE2 and the other using lung epithelial Calu-3 cells. From nearly 12,000 compounds, we identify 49 (in HeLa-ACE2) and 41 (in Calu-3) compounds capable of selectively inhibiting SARS-CoV-2 replication. Notably, most screen hits are cell-line specific, likely due to different virus entry mechanisms or host cell-specific sensitivities to modulators. Among these promising hits, the antivirals nelfinavir and the parent of prodrug MK-4482 possess desirable in vitro activity, pharmacokinetic and human safety profiles, and both reduce SARS-CoV-2 replication in an orthogonal human differentiated primary cell model. Furthermore, MK-4482 effectively blocks SARS-CoV-2 infection in a hamster model. Overall, we identify direct-acting antivirals as the most promising compounds for drug repurposing, additional compounds that may have value in combination therapies, and tool compounds for identification of viral host cell targets.

15 September 2021 in ACS Infectious Diseases
Verified
Journal Article
Open access
BFBarbara Forte
Barbara Forte
SOSabine Ottilie
Sabine Ottilie
APAndrew Plater
Andrew Plater
BCBrice Campo
Brice Campo
KDKoen J. Dechering
Koen J. Dechering
IGIan H. Gilbert
Ian H. Gilbert
There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in Plasmodium species. Given the high attrition rate and high cost of drug discovery, it is important to select the targets most likely to deliver progressible drug candidates. In this paper, we describe the criteria that we consider important for selecting targets for antimalarial drug discovery. We describe the analysis of a number of drug targets in the Malaria Drug Accelerator (MalDA) pipeline, which has allowed us to prioritize targets that are ready to enter the drug discovery process. This selection process has also highlighted where additional data are required to inform target progression or deprioritization of other targets. Finally, we comment on how additional drug targets may be identified.

30 September 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
SVSumiti Vinayak
Sumiti Vinayak
RJRajiv S. Jumani
Rajiv S. Jumani
PMPeter Miller
Peter Miller
MHMuhammad M. Hasan
Muhammad M. Hasan
BMBriana I. McLeod
Briana I. McLeod
ECEamon Comer
Eamon Comer
Bicyclic azetidines potently inhibit Cryptosporidium in vivo by targeting phenylalanyl-tRNA synthetase.

21 April 2023 in ACS Infectious Diseases
Verified
Journal Article
Open access
NCNicola Caldwell
Nicola Caldwell
RARana Afshar
Rana Afshar
BBBeatriz Baragaña
Beatriz Baragaña
ABAmaya L. Bustinduy
Amaya L. Bustinduy
Conor CaffreyConor Caffrey
Conor Caffrey
IGIan H. Gilbert
Ian H. Gilbert
In September 2022, the Drug Discovery Unit at the University of Dundee, UK, organised an international meeting at the Wellcome Collection in London to explore the current clinical situation and challenges associated with treating schistosomiasis. The aim of this meeting was to discuss the need for new treatments in view of the clinical situation and to ascertain what the key requirements would be for any potential new anti-schistosomals. This information will be essential to inform ongoing drug discovery efforts for schistosomiasis. We also discussed the potential drug discovery pathway and associated criteria for progressing compounds to the clinic. To date, praziquantel (PZQ) is the only drug available to treat all species causing schistosomiasis, but it is often unable to completely clear parasites from an infected patient, partially due to its inactivity against juvenile worms. PZQ-mediated mass drug administration campaigns conducted in endemic areas (e.g., sub-Saharan Africa, where schistosomiasis is primarily prevalent) have contributed to reducing the burden of disease but will not eliminate the disease as a public health problem. The potential for Schistosoma to develop resistance towards PZQ, as the sole treatment available, could become a concern. Consequently, new anthelmintic medications are urgently needed, and this Perspective aims to capture some of the learnings from our discussions on the key criteria for new treatments.

5 July 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BABree B. Aldridge
Bree B. Aldridge
DBDavid Barros-Aguirre
David Barros-Aguirre
CIClifton Earl Barry, III
Clifton Earl Barry, III
RBRobert H. Bates
Robert H. Bates
SBSteven J. Berthel
Steven J. Berthel
YYYing Yuan
Ying Yuan

18 March 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ASAnne Marie Sweeney-Jones
Anne Marie Sweeney-Jones
KGKerstin Gagaring
Kerstin Gagaring
JAJenya Antonova-Koch
Jenya Antonova-Koch
HZHongyi Zhou
Hongyi Zhou
NMNazia Mojib
Nazia Mojib
Julia KubanekJulia Kubanek
Julia Kubanek
A new cyclic peptide, kakeromamide B (1), and previously described cytotoxic cyanobacterial natural products ulongamide A (2), lyngbyabellin A (3), 18E-lyngbyaloside C (4), and lyngbyaloside (5) were identified from an antimalarial extract of the Fijian marine cyanobacterium Moorea producens. Compounds 1 and 2 exhibited moderate activity against Plasmodium falciparum blood-stages with EC50 values of 0.89 and 0.99 µM, respectively, whereas 3 was more potent with an EC50 value of 0.15 nM. Compounds 1, 4, and 5 displayed moderate liver-stage antimalarial activity against P. berghei liver schizonts with EC50 values of 1.1, 0.71, and 0.45 µM, respectively. The threading-based computational method FINDSITEcomb2.0 predicted the binding of 1 and 2 to potentially druggable proteins of Plasmodium falciparum, prompting formulation of hypotheses about possible mechanisms of action. Kakeromamide B (1) was predicted to bind to several Plasmodium actin-like proteins and a sortilin protein suggesting possible interference with parasite invasion of host cells. When 1 was tested in a mammalian actin polymerization assay, it stimulated actin polymerization in a dose-dependent manner, suggesting that 1 does, in fact, interact with actin.